UNSPSC 51151510: Galantamine

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C17H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0D3Q044KCA, chemically known as 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4as-(4a.alpha.,6.beta.,8ar*))- but generally known as galantamine, which bears US NIH Compound Identifier 3449. European Medicines Agency schedules Galantamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07870MIG.

UNSPSC 51151510 Galantamine is a Commodity code covering pharmaceutical products, though recent state and local solicitations tagged under this code show minimal direct relevance to galantamine specifically. Instead, issuing bodies are procuring naloxone (an opioid antagonist used in emergency overdose response) and related drug-management systems, along with broader pharmacy benefit program services that diverge significantly from the code's nominal scope. The mismatch suggests that state and local procurement offices may be applying this pharmaceutical commodity code to related emergency-response and pharmacy-administration work rather than to galantamine as a discrete product line. Buying entities include county health departments and state health and human services commissions, reflecting public-health and healthcare-administration mandates at multiple jurisdictional levels.

Seminole County, Florida solicited 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually through IFB 60459723LAS with a July 26, 2023 response deadline, requiring quarterly deliveries to the county community health building with vendor-paid shipping and delivery included. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs, seeking vendor capabilities for establishing relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. The geographic activity is sparse and scattered across Florida and Texas, with no indication of concentration or repeat buying patterns under this code. The mismatch between galantamine's abstract definition and the naloxone and pharmacy-services work actually being solicited signals that this code may not be a primary vehicle for sustained procurement activity in state and local markets.